Loading clinical trials...
Loading clinical trials...
Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Age
20 - 100 years
Sex
ALL
Healthy Volunteers
No
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Beitou, Taiwan
Start Date
April 29, 2024
Primary Completion Date
April 1, 2026
Completion Date
April 1, 2027
Last Updated
June 14, 2024
15
ESTIMATED participants
Ga-68-CXCR4
DRUG
Lead Sponsor
Koo Foundation Sun Yat-Sen Cancer Center
NCT05755087
NCT05672251
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions